During our October federal advocacy drop-in session, we learned about several pieces of legislation that had a good chance to pass before the end of
Assorted News from the Last Week: CAC2 Individual Member Jennifer Flowers writes compellingly about “When the National Drug Shortage Becomes Personal” for her. Published in
Assorted News from the Last Week: Last week the FDA reported that it is investigating reports of blood cancers — including life-threatening cases of myelodysplastic
Assorted News from the Last Week: In conjunction with the European Medicines Agency (EMA), the FDA Oncology Center of Excellence (OCE) held a one-hour Conversations
In conjunction with the European Medicines Agency (EMA), the FDA Oncology Center of Excellence (OCE) held a one-hour Conversations on Cancer public panel discussion on
Assorted News from the Last Week: Electronic symptom screening in kids with cancer boosts quality of care. DIPG Research in Nature: brain tumor yields, in
Assorted News from the Last Week: Navigating gatekeeping challenges in pediatric and young adult palliative oncology and end-of-life research. Active participation by patients and families
Assorted News from the Last Week: The NCI Fiscal Year 2026 Professional Judgment Budget Proposal highlights promising research areas and the optimal funding needed to
Assorted News from the Last Week: Today, the Biden Cancer Moonshot announced a new private sector pilot program to maintain uninterrupted access to seven pre-selected
The October 10 Federal Advocacy drop-in session covered three pieces of authorizing legislation and provided an update on possible appropriations for FY2025. Each of the
